We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Lab of the Future Post-COVID-19: Bringing User Experience to the Forefront
Industry Insight

UX designers are keen to help researchers adapt lab technology to fit remote working practices and prevent instances where company technology is bypassed completely. Here are five trends we expect to see in user experience in the life sciences (UXLS) post-COVID-19.

Read More

Accelerating Scientific Study With Scalable Single-Cell Sequencing
Industry Insight

Technology Networks recently interviewed Alex Rosenberg, co-founder and CEO of Parse Biosciences to learn more about the company and its novel approach to single-cell sequencing.

Read More

Filling in the Blanks of Leading LIMS: A Discussion With LIMS Wizards
Industry Insight

LIMS are powerful, but often complex tools. These big software packages can’t meet every need, and a growing field of companies has sprung up to offer labs supplementary tools. We spoke to Robert Jackson, Director of Delivery at LIMS Wizards, to find out more.

Read More

Could the “Spirit Molecule” DMT Assist in Stroke Recovery?
Industry Insight

N,N-dimethyltryptamine (DMT) is a psychedelic compound under investigation for a range of therapeutic uses. One avenue of research is being pursued by Algernon Pharmaceuticals, who are investigating whether sub-hallucinogenic DMT doses could help to protect and repair the brain in the hours after a stroke.

Read More

The Development of Plant-Based Medicines for Prescription
Industry Insight

Despite the fact that herbal or plant-based medicines are widely used and trusted by the public and have been for many years, few have been approved by regulatory agencies in the Western world as prescription medicines. But why have so few botanical medicines been approved?

Read More

180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases
Industry Insight

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

Read More

Exploiting the Therapeutic Potential of Plants
Industry Insight

Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”.

Read More

Paving the Way for Personalized Medicine in Sepsis
Industry Insight

In this interview, Dr Andreas Bergmann discusses how the quantification of two pathway-specific biomarkers can support the diagnosis, monitoring and treatment of sepsis patients.

Read More

Detecting Mutations With Liquid Biopsies
Industry Insight

Here we summarize the webinar that was hosted by Monika Seidel Ph.D., in which she discussed detecting mutations with liquid biopsies in cancer diagnostics.

Read More

What Are the Essential Features of a Biobanking LIMS?
Industry Insight

This year, more than ever, has underscored the critical services that biobanks provide to biomedical researchers and other scientists. By implementing a regulatory-compliant, configurable Laboratory Information Management System (LIMS), biobanks can follow best practice guidelines and overcome logistical, regulatory and safety challenges. This guide takes a look at how biobanks can choose the best LIMS to suit their operations.

Read More

 
Advertisement